



Note

Preparative production of colominic acid oligomers via a facile microwave hydrolysis

Jonathan Patane[†], Vincent Trapani[†], Janice Villavert, Katherine Dawn McReynolds^{*}

Department of Chemistry, California State University, Sacramento, 6000 J Street Sacramento, CA 95819-6057, United States

ARTICLE INFO

Article history:

Received 1 December 2008

Received in revised form 6 January 2009

Accepted 13 January 2009

Available online 19 January 2009

Keywords:

Colominic acid

Polysialic acid

Acid hydrolysis

Microwave irradiation

ABSTRACT

The hydrolysis of colominic acid via microwave irradiation was studied for the production of short-chain oligomers with a degree of polymerization (DP) of 1–5. This method was compared to the traditional acid hydrolytic method for the production of preparative quantities of short colominic acid oligomers. The oligomers were purified by size exclusion chromatography and characterized by ¹H NMR. Optimal conditions for producing the dimer were found to be 12 min at 10% power in a 1000-Watt domestic microwave. This method is advantageous over the traditional technique in that the hydrolysis can be completed in just a few minutes, rather than in a few hours, it is reproducible, and yields large quantities of the desirable short chain oligomers of colominic acid.

© 2009 Elsevier Ltd. All rights reserved.

Colominic acid is a capsular bacterial polysaccharide that was originally isolated from the culture filtrate of *Escherichia coli* K-235 by Barry and Goebel.¹ It is released from the cell wall surface into the culture medium by the acidic conditions that occur during the late growth phase of the bacteria.² These oligo-polymers consist of polydisperse linear chains of sialic acid linked α 2,8 (Scheme 1).^{3–5} The chain length of the colominic acid polymer is reported to range from a degree of polymerization (DP) of 60–80 to up to approximately 100.^{6,7} Colominic acid is known more generally as polysialic acid (polySia), and is present on the surface of other neuroinvasive bacteria, such as *Neisseria meningitidis* Group B.⁸ Structurally and immunologically identical polySia chains are found in the neural tissues of vertebrates, which are covalently attached to N-CAM (neural cell adhesion molecules). Due to the structural identity between the neuropathogenic bacterial polySia capsules and the α 2,8-linked polySia on mammalian N-CAM, polySia is non-immunogenic, and acts as a cloaking device for neurotropic bacteria to evade immune detection and facilitate meningeal infections.⁸ These bacteria are readily spread from person-to-person, and thus can lead to epidemics of bacterial meningitis that can be debilitating and fatal, when not diagnosed and treated early. Meningitis caused by the group B meningococci is especially dangerous for infants and young children, and there is currently no vaccine to prevent it.⁸

In mammals, polySia is found attached to N-CAM extending tri- and tetraantennary N-linked glycan chains.⁹ It lends a high nega-


tive charge density and hydrated volume to the cell surface. This can lead to diminution in cell–cell and cell–matrix interactions.^{9,10} The extended polySia chains on N-CAM are expressed primarily during embryonic development, and give plasticity to the cells, allowing for cell migration, axonal growth and synaptogenesis.¹⁰ PolySia, therefore, serves as an anti-adhesive glycotope during development.⁹ PolySia chain lengths peak during development, then get shorter as the organism progresses toward adulthood.^{8,10,11} Some regions of the brain, including the hippocampus, hypothalamus, dentate gyrus and olfactory bulb, express the embryonic or extended polySia chains into adulthood, thus allowing for plasticity in these regions of the brain throughout life. This long-term neural plasticity is associated with neuronal functions, including neural cell migration and generation, neurite outgrowth, cytokine response and reorganization of neural connections.^{8,10} For example, in mice, the loss of polysialylated N-CAM is associated with developmental and behavioral defects, and impaired learning.¹² Alteration of polySia expression on N-CAM is also important in the progression of certain diseases, including many human cancers principally of neuroendocrine origin, schizophrenia and Alzheimer's disease.^{9,11,13}

PolySia has the potential of being used in the preparation of therapeutic agents. Due to its low toxicity and lack of immunogenicity, it may be possible to extend peptide drug half lives through conjugation of the peptide with polySia. PolySia may also serve to minimize immune response to these drugs.^{14,15} Because of the biological importance of polySia, there is potential for this molecule to be used in the development of synthetic and semi-synthetic therapeutics. These applications may necessitate the generation of preparative quantities of short-chain oligomers in pure form.

^{*} Corresponding author. Tel.: +1 916 278 6551; fax: +1 916 278 4986.

E-mail address: kdmcr@csus.edu (K.D. McReynolds).

[†] These authors contributed equally to the study.



Scheme 1. Microwave acid hydrolysis of colominic acid.

Colominic acid oligomers that are purchased commercially can be prohibitively expensive (25 mg of hexamer for appx. \$1200)⁷ in the quantities needed for synthetic studies. Therefore, by starting with the commercially available form of polySia, colominic acid, preparative quantities of the necessary oligomers can be achieved at much less cost.

Short oligomers of colominic acid can be generated using traditional acid hydrolysis methods. Roy and Pon reported the use of an unbuffered acid hydrolysis using standard heating and various pH and temperature conditions to generate distributions of oligomers from colominic acid.¹⁶ Their reaction time required 30 min to 4 h to run, and was complicated by the unbuffered reaction solution because a constant pH had to be maintained over the course of the reaction. Later, Cheng and coworkers reported the use of acid hydrolysis via microwave irradiation to produce qualitative amounts (10–50 µg) of a wide range of oligomers with DPs ranging from monomer through unhydrolyzed products (DPs >200). These DPs were determined using MECC (micellar electrokinetic capillary chromatography).⁶

In our present study, we sought to generate quantitative amounts of a narrow DP distribution of colominic acid oligomers for use in the synthetic preparation of potential therapeutic agents. We initially targeted the dimer chain length to work with synthetically. Our experience with the traditional acid hydrolysis methods showed that it was time consuming, difficult to maintain the proper conditions, and highly variable from batch-to-batch with respect

to the amount of each DP that was generated (Table 1). Additionally, there was always a portion of high-molecular weight sialyl oligomers, which was not resolved by our preparative size exclusion chromatography column. This material was unusable for our synthetic studies, and thus resulted in an overall loss of expensive starting material (approximately \$200 per gram).⁷ It was thought that the microwave hydrolytic method of Cheng and coworkers could be used to develop an efficient, reproducible, and high yielding microwave hydrolytic method, whereby a narrow DP range of sialyl oligomers could be obtained in large quantities.

This method was simple to implement. Using a domestic 1000-W microwave oven and simple reaction glassware consisting of an Erlenmeyer flask, several conditions were tested for the acetic acid-catalyzed reaction (Scheme 1, Table 1). The reaction was neutralized with sodium hydroxide, lyophilized, and separated by preparative size exclusion chromatography. As all of the sialyl oligomers are known in the literature, confirmation of purity and oligomer length was conducted by proton NMR. In the NMR analysis, the integration of the protons corresponding to the methyl group of the *N*-acetate was compared to that of the non-reducing H_{3e} protons. Additionally, the total proton count was used as a measure of the oligomer purity (Fig. 1).

Using these methods, it was determined that higher power settings such as 20–30% did not work well, as the small volume of reaction solution boiled too quickly, and in some instances, either boiled over, resulting in a loss of material, or boiled dry during the

Table 1
Summary of traditional and microwave acid hydrolysis results

Trial	% Monomer	% Dimer	% Trimer	% Tetramer	% Pentamer	% Hexamer	% Unhydrolyzed
<i>Traditional</i>							
Trial 1	17.1	24.1	9.2	0.0	49.6	0	0
Trial 2	20.8	37.2	13.9	12.0	14.3	5	10.6
Trial 3	25.6	30.5	12.4	28.1	0	0	3.41
Std. Dev.	4.24	6.55	2.40	14.10	25.50	2.89	5.41
<i>Microwave</i>							
6 Min							
Trial 1	9.3	29.6	12.3	10.1	38.7	0	0
Trial 2	17.1	41.1	21.8	7.1	12.9	0	0
Std. Dev.	5.54	8.15	6.71	2.16	18.20	0	0
8 Min							
Trial 1	19.1	43.6	13.6	23.8	0	0	0
Trial 2	6.9	44.94	24.5	17.8	6.7	0	0
Trial 3	10	30.61	25.3	34.1	0	0	0
Std. Dev.	6.35	7.91	6.54	8.25	3.89	0	0
9 Min							
Trial 1	17.7	47.9	17.7	15.9	0.9	0	0
Trial 2	13.7	37	18.9	15.3	15.1	0	0
Std. Dev.	2.78	7.69	0.89	0.46	10.00	0	0
10 Min							
Trial 1	17.8	46.1	16.2	19.9	0	0	0
Trial 2	18.1	39.5	12.5	29.9	0	0	0
Std. Dev.	0.15	4.64	3.19	7.06	0	0	0
12 Min							
Trial 1	17.0	50.4	17.3	15.4	0	0	0
Trial 2	22.1	50.4	12.7	14.8	0	0	0
Std. Dev.	3.63	0.00	3.19	0.4	0	0	0

Each number is reported as a percentage of the total product recovered. The column entry listed as unhydrolyzed refers to mixtures of chain lengths greater than hexamer that were not resolved by the size exclusion column.




Figure 2. Optimization of microwave hydrolysis conditions for generating different DPs of PolySia. Graph shows the percent recovery of DPs 1–5 as a function of time at 20% power (6 min) and 8, 9, 10, and 12 min at 10% power. Results are representative of the average of two to three trials (Refer to Table 1).

1. Experimental

1.1. General

Colominic acid (approximate DP of 100) was purchased from Nacalai Tesque and was used without further purification. All microwave hydrolyses were carried out in a domestic microwave oven (Emerson, 1000 W, model number MW8111SS). ^1H NMRs were conducted in D_2O (Acros) at 300 MHz on a Bruker AVANCE NMR. The spectra were processed using Spinworks 2.4.

1.2. Microwave hydrolysis of colominic acid

Approximately 100 mg of colominic acid was added to a 50 mL Erlenmeyer flask. The colominic acid was dissolved into 4 mL of 0.1 M acetic acid using a graduated pipet. The flask was then covered with plastic wrap and a rubber band, and several holes were added for ventilation. Microwave hydrolysis was carried out in a 1000 W conventional Emerson microwave oven with the flask placed in an alumina bath. The reaction was run at either 10% or 20% power with heating periods of 6, 8, 9, 10, or 12 min. The sam-




Figure 3. Comparison of the traditional and microwave hydrolysis methods for generating sialyl oligomers with DPs 1–7. Graph shows the DP and quantity of each chain length of colominic acid produced in 12 min at 10% power in the microwave method versus 3 h at 70 °C at pH 3.0 by traditional acid hydrolytic method. Results are representative of the average of two to three trials (Refer to Table 1).

ple was neutralized to a pH of 7.0 using 0.1 M NaOH and freeze dried. The resultant white solid was weighed to determine an overall percent recovery.

1.3. Purification and characterization of colominic acid oligomers

The oligomeric mixtures generated by either the microwave or acid hydrolysis methods were dissolved in less than 2.0 mL of 0.03 M ammonium bicarbonate buffer, centrifuged, and injected into a Pharmacia Liquid Chromatography FPLC using a 5 mL syringe. A Biogel P-10 size exclusion column, 2.5 × 120 cm, was used to separate the oligomers. The column was run at a flow rate of 0.25 mL per minute, with 125 total fractions collected at a volume 3.5 mL per fraction. The fractions were pooled and freeze dried as individual peaks. Dialysis against pure distilled water was carried out using Spectrum Cellulose Ester 100 MWCO tubing, and was performed when necessary to remove excess salt impurities from the pure oligomers. ¹H NMR analyses were conducted in D₂O to confirm the chain lengths. The DP was confirmed by comparison of the integration of the *N*-acetyl methyl peak with the integration of the H_{3e} non-reducing signal, as well as the overall proton count.

1.4. Traditional acid hydrolysis of colominic acid

The traditional acid hydrolysis of colominic acid was carried out according to the procedure reported by Roy and Pon.¹⁶ Approximately 100 mg of colominic acid was added to a 50 mL round-bottomed flask and dissolved into 10 mL of deionized water, and the pH was adjusted to approximately 3.0 using 1 M hydrochloric acid. The hydrolysis was carried out at 70 °C in an oil bath for 3 h. Recordings of the temperature and the pH were taken every 15 min and the pH was adjusted accordingly with acid and/or base to keep the pH constant at ~3.0. The sample was neutralized to pH 7.0 using 0.1 M sodium hydroxide, then freeze dried. The resultant

white solid was weighed to determine an overall percent recovery. Purification of the oligomeric mixture was performed as described above.

Acknowledgments

The authors appreciate the support of the California State University Department of Chemistry and funding received through a Research Corporation Cottrell College Science Award, NIH-NIAID AREA Grant, and a CSUPERB (California State University Program for Education and Research in Biotechnology) Entrepreneurial Joint Venture Grant.

References

- Barry, G. T.; Goebel, W. F. *Nature* **1957**, 179, 206.
- Troy, F. A. I.; McCloskey, M. A. *J. Biol. Chem.* **1979**, 254, 7377–7387.
- Barry, G. T. *J. Exp. Med.* **1958**, 107, 507–521.
- McGuire, E. J.; Binkley, S. B. *Biochemistry* **1964**, 3, 247–251.
- Rodriguez-Aparicio, L. B.; Reglero, A.; Ortiz, A. I.; Luenga, J. M. *Appl. Microbiol. Biotechnol.* **1988**, 27, 474–483.
- Cheng, M.-C.; Wang, K.-T.; Inoue, S.; Inoue, Y.; Khoo, K.-H.; Wu, S.-H. *Anal. Biochem.* **1999**, 267, 287–293.
- Nacalai USA, 2008, <http://www.nacalaiusa.com/product.php?id=33>, Accessed 01/06/09.
- Stein, D. M.; Robbins, J.; Miller, M. A.; Lin, F.-Y. C.; Schneerson, R. *Vaccine* **2006**, 24, 221–228.
- Nakata, D.; Troy, F. A. I. *J. Biol. Chem.* **2005**, 280, 38305–38316.
- Gascon, E.; Vutskits, L.; Kiss, J. Z. *Brain Res. Rev.* **2007**, 56, 101–118.
- Easton, E. W.; Schiphorst, W. E. C. M.; Koeleman, C. A. M.; Michalides, R. J. A. M.; Van Den Eijnden, D. H. *Glycoconjugate J.* **1995**, 12, 829–837.
- Cremer, H.; Lange, R.; Christoph, M.; Plomann, M.; Vopper, G.; Roes, J.; Brown, R.; Baldwin, S.; Kraemer, P.; Scheff, S.; Barthels, D.; Rajewsky, K.; Wille, W. *Nature* **1994**, 367, 455–459.
- Angata, K.; Fukuda, M. *Biochimie* **2003**, 85, 195–206.
- Gregoriadis, G.; Fernandes, A.; Mital, M.; McCormack, B. *Cell Mol. Life Sci.* **2000**, 57, 1964–1969.
- Gregoriadis, G.; Jain, S.; Papaioannou, I.; Laing, P. *Int. J. Pharm.* **2005**, 300, 125–130.
- Roy, R.; Pon, R. A. *Glycoconjugate J.* **1990**, 7, 3–12.